Sept 21 (Reuters) - Gilead Sciences Inc GILD.O :
* Gilead receives approval in Canada for expanded indication of epclusa (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C in patients co-infected with HIV
* Gilead Sciences Inc - safety profile of epclusa in hcv/hiv co-infected patients was similar to that observed in hcv mono-infected patients